Container Closure Integrity
Integrity of the closure of a drug product container/delivery systems is crucial to guarantee safety and efficacy. Methods (deterministic and probabilistic) to measure this have recently been set forth in USP Chapter 1207. This section presents papers discussing methods (e.g., helium leak, gas headspace, high-voltage leak detection) and their application to various systems.
Register below for access to our Online Technical Repository and for current customers, our Online Technical Customer Support Portal.
This study compares plastic container systems for suitability for storing and shipping cell therapy products at low temperatures.<br />
This report describes finding appropriate capping parameters for four NP RP vial-stopper combinations, and the corresponding CCI investigation.
<br class="Apple-interchange-newline" /> <span style="text-align: left; color: #000000; letter-spacing: normal; background-color: #ffffff;">Reviews West's Analytical Services container closure integrity (CCI) offering using High Voltage Leak Detection (HVLD). USP chapter <1207> on Package Integrity Evaluation is highlighted.</span>
This bulletin outlines the design intent of Article 2340/2345 and NovaPure® 1 mL Long/1-3 mL plungers, related to primary sealing rib and seal integrity.
Examination of CZ syringes delivering various fill volumes and dispensing high viscosity solutions typical of high concentration biologic formulations.
This poster investigates CCI properties of glass vs COP at cold temperatures using headspace oxygen and headspace pressure.
Different methods used to determine suitability of a container for its potential drug product, to help drive further testing during component selection.
Pre-filled syringe and cartridge systems pose unique challenges regarding container closure integrity (CCI) analysis. With the advent of USP chapter <1207>, the industry is now better guided regarding applicable technology and proper method validation processes. This presentation will examine how deterministic methods can be applied, individually, and in combination, to evaluate syringes and cartridges at temperatures from ambient to cryogenic (critical for biologic and cell therapies).
Discusses proper sealing parameters and the effects of temperature and time on vial/stopper performance and CCI.
The container closure system (CCS) determines container closure integrity (CCI) performance, and CCI quality is essential for drug product integrity throughout the entire sealed drug product life cycle.
Radiolabeled protein molecules are used to demonstrate that there is less adhesion to a vial made of Daikyo Crystal Zenith® cyclic olefin polymer (COP) than to a glass vial, and that COP enables better recovery of protein. <p><em>A. Leece, et al. Applied Radiation and Isotopes, 80, 99-102 (2013)</em></p>
Contained is summary discussion of seven plenary sessions of the subject PDA conference.<br /> <br /> Plenary 1: The Future of Drug Delivery<br /> Plenary 2: Strategies for Safety Evaluation<br /> Plenary 3: Leachables and Extractables for Combination Products that Include Both Drugs and Devices<br /> Plenary 4: Holistic Safety and Quality Assessment<br /> Plenary 5: Particle Challenges Associated with Delivery Systems and Devices<br /> Plenary 6: Compatibility of Delivery Systems with Biologics<br /> Plenary 7: Quality Considerations for Combination Products and Device<br /> <br /> <em>(co-sponsored with the Product Quality Research Institute (PQRI), Oct. 2–3, in Washington, D.C.)</em>
This article demonstrates that vials comprising Daikyo Crystal Zenith<sup><sup>®</sup></sup> cyclic olefin polymer are well-suited to cryogenic storage/transport of cell therapy products. <p><em>E. Woods, et al. Regen. Med., 5 (4), 659-667 (2010)</em></p>
This article considers how changes to USP Chapter 1207 will affect the measurement of container closure integrity for drug product packaging systems. <p><em>H. Forcinio. Pharmaceutical Technology, 39 (4) 76-77 (2015)</em></p>
<p>This article describes properties of cyclic olefin polymer and its ability to maintain container closure integrity under cryogenic conditions, as well as its transparency and fracture resistance. </p> <p><em>PDA Letter written by James McCaw of West Pharmaceutical Services, Inc.</em></p>
This report discusses FDA thoughts on how both sterility testing and container closure integrity testing may be used to evaluate the performance of drug product packaging systems.
This article considers the fundamentals of gas headspace analysis for the measurement of container closure integrity – the physics of the process is described along with the types of containers for which it is suitable. <p><em>D.I. Duncan and J.R. Veale (Lighthouse Instruments)</em></p>
This presentation considers several different methods of measuring container closure integrity, and compares their relative utilities: (a) vacuum decay (loss of vacuum in evacuated chamber due to failure of container), dye ingress (visual observation of colorized fluid moving into container), ultrasonic (air pockets where container components join). <p><em>H. Wolf (PTI Inspection Systems)</em></p>
This poster considers the use of gas headspace analysis for the measurement of container closure integrity of syringes. The method can distinguish differences in gas permeability between plunger and tip, and between staked needle and Luer lock configurations. <p><em>J.R. Veale and K.G. Victor (Lighthouse Instruments). PDA Universe of Pre-filled Syringes & Injection Devices Conference (2016)</em></p>
NovaPure®, FluroTec® and Ready Pack®are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd.
Daikyo Crystal Zenith® technology is a registered trademark of Daikyo Seiko, Ltd.